Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eyevance Pharmaceuticals LLC.

https://eyevance.com/

Latest From Eyevance Pharmaceuticals LLC.

Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy

Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.

Ophthalmic M & A

Start-Up Quarterly Statistics: Financings Surged In Q4 While M&A Waned

A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.

Deals Financing

Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials

Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.

Deals Business Strategies

Asia Deal Watch: Zogenix Partners Japanese Rights To Pediatric Epilepsy Therapy To Nippon Shinyaku

Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.

Asia Pacific Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Eyevance Pharmaceuticals, LLC
UsernamePublicRestriction

Register